focus -WSS

focus

author：hotspot 2025-10-08 19:12:50 - browse：63

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Study finds new variant for Parkinson’s in African populations

focus

WSS

CDC advisory panel says seniors 'may' get RSV vaccine

Dewpoint Therapeutics lays off staff after losing partnerships

In science, is the line between industry and academia shifting?

In science, is the line between industry and academia shifting?

Parkinson’s finding may lead to tests and, someday, treatments

As pharma fights Medicare drug negotiation, hospitals, docs silent

knowledge

focus

focus

Moonlake's readout produced a cash windfall. Risks remain

Independent physicians launch a new lobbying group

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

AI generated plenty of interest at JPM but not a lot of trust

Hepatitis C has a cure — but many Americans still lack access to it

How digital therapeutics firms are pivoting after Pear's bankruptcy

In Memoriam: Notable people who died in 2023

Eli Lilly, Pfizer, and others want in on the online prescription market

At least 13 dead in Texas as scorching temps continue

As pharma fights Medicare drug negotiation, hospitals, docs silent

focus

How to make Best Hospitals ratings actually useful for patients

Test for long Covid? Researchers find new clue in blood samples

Radiation, mainstay of cancer treatment, begins a fade

What do new weight loss drugs mean for bariatric surgery?

What AAP's gender

Feds fine Medicare Advantage plans for overcharging members

focus

focus

leisure time

Wikipedia